Santhera Pharmaceuticals Holding AG

SWX:SANN Stock Report

Market Cap: CHF 96.8m

Santhera Pharmaceuticals Holding Valuation

Is SANN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SANN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SANN (CHF8) is trading below our estimate of fair value (CHF618.79)

Significantly Below Fair Value: SANN is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SANN?

Key metric: As SANN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SANN. This is calculated by dividing SANN's market cap by their current earnings.
What is SANN's PE Ratio?
PE Ratio1.5x
EarningsCHF 62.86m
Market CapCHF 96.85m

Price to Earnings Ratio vs Peers

How does SANN's PE Ratio compare to its peers?

The above table shows the PE ratio for SANN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average23.1x
CGEN Compugen
79x-59.8%US$126.2m
OBSN ObsEva
0.02xn/aCHF 140.6k
2142 HBM Holdings
5.4xn/aHK$894.2m
XLS Xlife Sciences
7.9xn/aCHF 167.1m
SANN Santhera Pharmaceuticals Holding
1.5x35.4%CHF 96.8m

Price-To-Earnings vs Peers: SANN is good value based on its Price-To-Earnings Ratio (1.5x) compared to the peer average (23.1x).

Price to Earnings Ratio vs Industry

How does SANN's PE Ratio compare vs other companies in the European Biotechs Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.27.0x42.4%
SANN Santhera Pharmaceuticals Holding
 1.5x35.4%US$108.30m
SANN 1.5xIndustry Avg. 27.0xNo. of Companies5PE020406080100+
5 CompaniesEstimated GrowthMarket Cap
Industry Avg.27.0x42.4%
SANN Santhera Pharmaceuticals Holding
 1.5x35.4%US$108.30m
No more companies

Price-To-Earnings vs Industry: SANN is good value based on its Price-To-Earnings Ratio (1.5x) compared to the European Biotechs industry average (27x).

Price to Earnings Ratio vs Fair Ratio

What is SANN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SANN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio1.5x
Fair PE Ratio18.9x

Price-To-Earnings vs Fair Ratio: SANN is good value based on its Price-To-Earnings Ratio (1.5x) compared to the estimated Fair Price-To-Earnings Ratio (18.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SANN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 8.00
CHF 32.00
+300.0%
21.9%CHF 39.00CHF 25.00n/a2
Nov ’25CHF 8.77
CHF 32.00
+264.9%
21.9%CHF 39.00CHF 25.00n/a2
Oct ’25CHF 9.17
CHF 32.00
+249.0%
21.9%CHF 39.00CHF 25.00n/a2
Sep ’25CHF 9.00
CHF 34.50
+283.3%
13.0%CHF 39.00CHF 30.00n/a2
Aug ’25CHF 9.29
CHF 34.50
+271.4%
13.0%CHF 39.00CHF 30.00n/a2
Jul ’25CHF 8.51
CHF 34.50
+305.4%
13.0%CHF 39.00CHF 30.00n/a2
Jan ’25CHF 9.81
CHF 71.00
+623.8%
57.7%CHF 112.00CHF 30.00n/a2
Dec ’24CHF 9.59
CHF 70.00
+629.9%
60.0%CHF 112.00CHF 28.00n/a2
Nov ’24CHF 10.82
CHF 70.00
+547.0%
60.0%CHF 112.00CHF 28.00CHF 8.772
Oct ’24CHF 8.34
CHF 68.00
+715.3%
64.7%CHF 112.00CHF 24.00CHF 9.172
Sep ’24CHF 8.64
CHF 68.00
+687.0%
64.7%CHF 112.00CHF 24.00CHF 9.002
Aug ’24CHF 8.59
CHF 68.00
+691.6%
64.7%CHF 112.00CHF 24.00CHF 9.292
Feb ’24CHF 8.79
CHF 88.00
+901.1%
54.5%CHF 136.00CHF 40.00CHF 9.352
Jan ’24CHF 13.80
CHF 88.00
+537.7%
54.5%CHF 136.00CHF 40.00CHF 9.812

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Gerresheimer

€2.6b

Manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally.

GXI

€75.60

7D

0%

1Y

0%

Roche Holding

CHF 204.3b

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania.

ROG

CHF 254.30

7D

-0.6%

1Y

6.5%

Cosmo Pharmaceuticals

CHF 1.0b

Focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide.

COPN

CHF 62.80

7D

-1.3%

1Y

58.4%